Document:

Exhibit 10.18

EXECUTIVE EMPLOYMENT AGREEMENT

As of the 1st day of October, 2006

BY AND BETWEEN: 

VALTECH COMMUNICATIONS INC., a body politic and corporate, duly incorporated according to law, having a place of establishment in the City and District of Montreal, Province of Quebec, and therein located at 759 Square Victoria, Suite 200, H2Y 2J7, herein represented by Mr. PETER VARADI, its Secretary, duly authorized for these purposes, as he so declares, hereinafter referred to and designated as:

"VALTECH"

AND: 

RENE ARBIC, Businessman, of the City of Brossard, Province of Quebec, J4SX 2G7, and therein residing at 1095 Renoir, hereinafter referred to and designated as the:

"EXECUTIVE"

WHEREAS "VALTECH" is desirous of retaining the services of "EXECITIIVE" for the purposes of fulfilling the position of President, on behalf of "VALTECH", subject to such terms and conditions as are hereinafter to be more fully enumerated;

WHEREAS the "EXECUTIVE" is desirous of becoming gainfully employed by "VALTECH" and to render such services as may be required of him acting as the President of "VALTECH", subject, however, to such terms and conditions as are hereinafter to be more fully enumerated;

NOW, THEREFORE, IN CONSIDERATION OF THE MUTUAL PROMISES AND THE FOLLOWING COVENANTS, CONDITIONS AND AGREEMENTS, THE PARTIES HERETO DO HEREBY MUTUALY AGREE AS FOLLOWS:

1. Preamble

The preamble herein recited above shall form an integral part of the present "Executive Employment Agreement".

2. Employment and Job Description.

"VALTEC1I" hereby agrees to initially employ "EXECUTIVE" as its President, on behalf of "VALTECH", and Executive hereby accepts such employment in accordance with the terms of this "Agreement" and the terms of employment applicable to regular employees of "VALTECH". In the event of any conflict or ambiguity between the terms of this "Agreement" and terms of employment applicable to regular employees, the terms of this "Agreement" shall prevail.

The "EXECUTIVE" shall have a direct reporting obligation and relationship with the Officers of "VALTECH", and "VALTECH" agrees to provide equal and free access to the aforesaid individuals in order for "EXECUTIVE" to perform his duties during the term of this "Agreement" and/or any extension thereof

 

1

 

3. Duties of Executive.

The duties of "EXECUTIVE" shall include the performance of all of the duties typical of the office held by "EXECUTIVE" as described in the bylaws of "VALTECH", if any, or as may be directed by the Board of Directors of "VALTECH". "EXECUTIVE" shall devote his entire productive time, ability and attention to the business of "VALTECH" and shall perform all duties in a professional, ethical and businesslike manner. "EXECUTIVE" will not, during the term of this "Agreement", directly or indirectly engage in any other business, either as an employee, employer, consultant, principal, officer, director, advisor, or in any other capacity, either with or without compensation, without the prior written consent of the Secretary and Vice-President of "VALTECH", save and except for those Boards of public and private companies on which the "EXECUTIVE" presently serves.

Your employment on a full-time basis, during the term of this "Agreement", shall be located at the offices of "VALTECI", to be located on Nun's island, Montreal, Quebec, or at such location as may be determined by 11 VALTECH" during the term. hereof.

4. Compensation.

Executive will be paid the following base salary as forming part of his compensation package, as hereinafter enumerated, during this "Agreement" as follows:

A. 1) A base salary for the period October 1st, 2006 to September 30a', 2007 of EIGHTY THOUSAND DOLLARS ($80,000.00) per year, payable in installments according to "VALTECH"'s regular payroll schedule.

5. Benefits.

A. Holidays. "EXECUTIVE" will be entitled to at least three (3) weeks paid holidays each calendar year, not to be taken consecutively. "EXECUTIVE" will notify "VALTECH" on or about the beginning of each calendar year with respect to the holiday schedule for the coming year.

B. Sick Leave "EXECUTIVE" shall be entitled to sick leave and emergency leave according to the regular policies and procedures of "VALTECH". Additional sick leave or emergency leave over and above paid leave provided by "VALTECH", if any, shall be unpaid and shall be granted at the discretion of the Board of Directors.

C. Expense Reimbursement. "EXECUTI'V'E" shall be entitled to the reimbursement of all reasonable gas and cellular telephone expenses incurred by "EXECUTIVE" in the performance of "EXECUTIVE"s duties. "EXECUTIVE" will maintain records and written receipts as required by "VALTECH"s policies and as may be reasonably requested by the Board of Directors to substantiate such expenses.

D. Additional compensation. That the parties hereto further undertake and agree to reimburse "EXECUTIVE" by the payment to him of Ten Thousand Dollars ($10,000.00) Cdn. currency, to adjust the advances provided by him to "VALTECH" for the period up to and including September 30th, 2006, and "EXECUTIVE", in consideration of the foregoing, does hereby release and forever discharge "VALTECH" from any and all claims of any nature whatsoever, which "EXECUTIVE!" may have, had or pretend to have for the period up to and including September 30th, 2006;

6. Term and Termination.

A. The Initial Term of this "Agreement" shall commence on October 1's, 2006 and it shall continue in effect for a period of Twelve (12) months, terminating on September 30th, 2007. Thereafter, the "Agreement" shall be renewed upon the mutual agreement of "EXECUTIVE" and "VALTECH". This "Agreement" and "EXECUTIVE"'s employment may be terminated at "VALTECH"'s discretion during the Initial Term, provided that "VALTECH" shall pay to "EXECUTIVE" an amount equal to payment of "EXECUTIVE'"s base salary remaining to be paid for the initial year of the term, but in no case, shall it exceed six (6) months' base salary. In the event of the non-renewal of this Agreement at the expiration of one (1) year or any annual extension hereof, "EXECUTIVE" shall be entitled to a severance package of one (1) month's base salary for each year of his employment, payable in installments, according to "VALTECH"'s regular payroll schedule.

 

2

 

B. In the event that this "Agreement" is terminated by "EXECUTIVE", for any reason whatsoever, "VALTECH" may immediately relieve "EXECUTIVE" of all duties and immediately terminate this "Agreement".

C. In the event that "EXECUTIVE" is in breach of any material obligation owed "VALTECH" in this "Agreement", habitually neglects the duties to be performed under this "Agreement", engages in any conduct which is dishonest, damages the reputation or standing of "VALTECH", or is convicted of any criminal act or engages in any act of moral turpitude, then "VALTECH" may terminate this "Agreement" upon five (5) days written notice to "EXECUTIVE". In event of termination of the "Agreement" pursuant to this subsection, "EXECUTIVE" shall be paid only at the then applicable base salary rate up to and including the date of termination. "EXECUTIVE" shall not be paid any incentive salary payments or other compensation, prorated or otherwise.

D. In the event that "EXECUTIVE" is disabled, for any reason whatsoever, and is physically or mentally unable to perform his duties for a period of four (4) consecutive months, then the present "Agreement" may be terminated by "VALTECH" at its option

7. Notices.

Any notice required by this "Agreement" or given in connection with it, shall be in writing and shall be given to the appropriate party by personal delivery or by certified mail, postage prepaid, or recognized overnight delivery services;

If to "VALTECH":

VALTECH COMMUNICATIONS INC. 

759 Square Victoria,

Suite 200,

Montreal, Quebec

H2Y 237

Attention: Mr. Peter Varadi 

With a copv to:

Mtre. Morden C. Lazarus

Lazarus, Charbonneau, Advocates 

759 Square Victoria, Suite 200 

Montreal, Quebec, H2Y 217

Fax No.:

(514) 289-8609)

(E-mail:

cookie@lazaruscharbonneau.com)

If to "EXECUTIVE":

RENE ARBIC 

1095 Renoir

Brossard, Quebec 14X 2G7

(E-mail.

rene.arbic@videotron.ca)

8. Final Agreement.

This "Agreement" terminates and supersedes all prior understandings or agreements on the subject matter hereof. This "Agreement" may be modified only by a further writing that is duly executed by both parties.

9. Governing Law.

This "Agreement" shall be construed and enforced in accordance with the laws of the Province of Quebec.

10. Headings.

Headings used in this "Agreement" are provided for convenience only and shall not be used to construe meaning or intent.

11. No Assignment.

Neither this "Agreement" nor any rights and/or interests herein stipulated and/or contained in this "Agreement" may be assigned by "EXECUTIVE" without the prior express written approval of "VALTECH", which may be withheld by "VALTECH" at "VALTECH"'s absolute discretion.

 

3

 

12. Severability.

If any term of this "Agreement" is held by a court of competent jurisdiction to be invalid or unenforceable, then this "Agreement", including all of the remaining terms, will remain in full force and effect as if such invalid or unenforceable term had never been included.

13. Arbitration.

The parties agree that they will use their best efforts to amicably resolve any dispute arisingout of or relating to this "Agreement". Any controversy, claim or dispute that cannot be so resolved shall be settled by final binding arbitration in accordance with the rules of the Code of Civil Procedure and the provisions therein contained regarding arbitration and resolution of disputes. Any such arbitration shall be conducted in the City and District of Montreal, Province of Quebec, or such other place as may be mutually agreed upon by the parties. Within fifteen (15) days after the commencement of the arbitration, each party shall select one person to act as arbitrator, and the two arbitrators so selected shall select a third arbitrator within ten (10) days of their appointment. Each party shall bear its own costs and expenses and an equal share of the Arbitrator's expenses and administrative fees of arbitration.

14. Language.

The parties hereto acknowledge that they have requested and are satisfied that the foregoing and all related documents be drawn up in the English language. Les parties aux presentes reconnaissent qu'elles ont exige que ce qui precede et tous documents qui s'y rattache soient rediges et executes en anglais et s'en declarent satisfaits.

IN WITNESS WHEREOF, the parties hereto have executed this "Agreement" as of the date first above written.

SIGNED, SEALED AND DELIVERED BY

VALTECH COMMUNCATIONS INC. 

In the presence of

/s/ Alex Kestenbaum

2170 Duy Collier

QC

Address

VP Finance

Occupation

Name

/s/Peter Varadi

 

President

Authorized Signature

RENE ARBIC

\

In the presence of 

/s/Linda Hamel

Name

156 Thomas Chapais

Ste Julie (PQ)

/s/Rene Arbic

Address

RENE ARBIC

Authorized Signature

Paralegal

Occupation

 

4Exhibit 10.1

 

VOTING AGREEMENT

 

VOTING AGREEMENT (this “Agreement”), dated as of June 29,
2009, by and among BioSante Pharmaceuticals, Inc., a Delaware corporation
(“BioSante”), and the undersigned stockholder (“Stockholder”) of
Cell Genesys, Inc., a Delaware corporation (the “Company”),
identified on the signature page hereto.

 

RECITALS:

 

WHEREAS, the Company and BioSante are entering into an
Agreement and Plan of Merger (as amended from time to time, the “Merger
Agreement”), dated as of the date hereof, providing for, among other
things, the merger of the Company with and into BioSante, with BioSante
continuing as the surviving corporation (the “Merger”);

 

WHEREAS, as of the date hereof, Stockholder is the
Beneficial Owner (as defined below) of, and has the sole right to vote and
dispose of, that number of shares of common stock (the “Company Shares”)
of the Company set forth beside Stockholder’s name on Schedule A hereto; and

 

WHEREAS, concurrently with the entry by the Company and
BioSante into the Merger Agreement, and as a condition and inducement to the
willingness of BioSante to enter into the Merger Agreement and incur the
obligations set forth therein, BioSante has required that Stockholder enter
into this Agreement;

 

NOW, THEREFORE, in consideration of the foregoing and
the mutual representations, warranties, covenants and agreements contained
herein, the parties hereto, intending to be legally bound, hereby agree as
follows:

 

ARTICLE I

DEFINITIONS

 

Capitalized terms used but not defined in this Agreement
are used in this Agreement with the meanings given to such terms in the Merger
Agreement.  In addition, for purposes of
this Agreement:

 

“Affiliate” means, with respect to any specified
person, a person who, at the time of determination, directly or indirectly
through one or more intermediaries, controls, or is controlled by, or is under
common control with, such specified person. 
For purposes of this Agreement, with respect to Stockholder, “Affiliate”
shall not include the Company and the persons that directly, or indirectly
through one or more intermediaries, are controlled by the Company.  For the avoidance of doubt, no officer or
director of the Company shall be deemed an Affiliate of another officer or director
of the Company by virtue of his or her status as an officer or director of the
Company.

 

“Beneficially Owned” or “Beneficial Ownership”
with respect to any securities means having beneficial ownership of such
securities (as determined pursuant to Rule 13d-3 under the Exchange Act,
disregarding the phrase “within 60 days” in paragraph (d)(1)(i) thereof),
including pursuant to any agreement, arrangement or understanding, whether or
not in writing.  

 

 

Without duplicative counting of
the same securities, securities Beneficially Owned by a person shall include
securities Beneficially Owned by (i) all Affiliates of such person, and (ii) all
other persons with whom such person would constitute a “group” within the
meaning of Section 13(d) of the Exchange Act and the rules promulgated
thereunder.

 

“Beneficial Owner” with respect to any securities
means a person that has Beneficial Ownership of such securities.

 

“person” shall have the meaning ascribed thereto
in the Merger Agreement.

 

“Subject Shares” means, with respect to
Stockholder, without duplication, (i) the Company Shares owned by
Stockholder on the date hereof as described on Schedule A, and (ii) any
additional Company Shares acquired by Stockholder or over which Stockholder
acquires Beneficial Ownership from and after the date hereof, whether pursuant
to existing stock option agreements or otherwise.

 

“Transfer” means, with respect to a security, the
sale, transfer, pledge, hypothecation, encumbrance, assignment or disposition
of such security or the Beneficial Ownership thereof, and each option,
agreement, arrangement or understanding, whether or not in writing, to effect
any of the foregoing.  As a verb, “Transfer”
shall have a correlative meaning.

 

ARTICLE II

COVENANTS OF STOCKHOLDER

 

Section 2.1             Irrevocable Proxy.  Concurrently with the execution of this
Agreement, Stockholder agrees to deliver to BioSante a proxy in the form
attached hereto as Exhibit A (the “Proxy”), which shall be
irrevocable to the extent provided in Section 212 of the Delaware General
Corporation Law (the “DGCL”), with respect to the Subject Shares
referred to therein.

 

Section 2.2             Agreement to Vote.

 

(a)           At
any meeting of the stockholders of the Company held prior to the Expiration
Date (as defined in Section 5.13), however called, and at every
adjournment or postponement thereof prior to the Expiration Date, or in
connection with any written consent of, or any other action by, the
stockholders of the Company given or solicited prior to the Expiration Date,
Stockholder shall vote, or provide a consent with respect to, all of the
Subject Shares entitled to vote or to consent thereon (i) in favor of the
adoption of the Merger Agreement, and any actions required in furtherance
thereof and (ii) against any Acquisition Proposal, against any amendment
of the Company’s Certificate of Incorporation or Bylaws or any other proposal
or transaction involving the Company, the purpose of which amendment or other
proposal or transaction is to delay, prevent or nullify the Merger or the
transaction contemplated by the Merger Agreement or change in any manner the
voting rights of any capital stock of the Company, and against any other action
or agreement that would result in a breach in any material respect of any
covenant, representation or warranty or any other obligation or agreement of
the Company under the Merger Agreement.

 

2

 

(b)           Stockholder
shall not enter into any agreement with any person (other than BioSante) prior
to the Expiration Date (with respect to periods prior to or after the
Expiration Date) directly or indirectly to vote, grant any proxy or give
instructions with respect to the voting of, the Subject Shares in respect of
the matters described in Section 2.2 hereof, or the effect of which would
be inconsistent with or violative of any provision contained in this Section 2.2.  Any vote or consent (or withholding of
consent) by Stockholder that is not in accordance with this Section 2.2
shall be considered null and void, and the provisions of the Proxy shall be
deemed to take immediate effect.

 

Section 2.3             Revocation of Proxies; Cooperation.  Stockholder agrees as follows:

 

(a)           Stockholder hereby represents and
warrants that any proxies heretofore given in respect of the Subject Shares
with respect to the matters described in Section 2.2(a) hereof are
not irrevocable, and Stockholder hereby revokes any and all prior proxies with
respect to such Subject Shares as they relate to such matters.  Prior to the Expiration Date, Stockholder
shall not directly or indirectly grant any proxies or powers of attorney with
respect to the matters set forth in Section 2.2(a) hereof (other than
to BioSante), deposit any of the Subject Shares or enter into a voting
agreement (other than this Agreement) with respect to any of the Subject Shares
relating to any matter described in Section 2.2(a).

 

(b)           Stockholder will (i) use all
reasonable efforts to cooperate with the Company and BioSante in connection
with the transactions contemplated by the Merger Agreement, and (ii) provide
any information reasonably requested by the Company or BioSante for any
regulatory application or filing sought for such transactions.

 

Section 2.4             No Solicitation.

 

(a)           Stockholder acknowledges
that the Company is subject to the non-solicitation prohibitions set forth in Section 7.05 of the Merger Agreement and that the Stockholder
has read and understands the terms thereof.

 

(b)           Notwithstanding anything to the
contrary contained in this Agreement, (i) the provisions of this Section 2.4
apply solely to Stockholder when acting in his, her or its capacity as a
stockholder of the Company and not when acting as an officer or director of the
Company (it being understood that the Company has separate and independent
obligations to BioSante under the Merger Agreement, including, without
limitation, Section 7.05 thereof); and (ii) none of the provisions of
this Section 2.4 shall be construed to prohibit, limit or restrict
Stockholder from exercising Stockholder’s fiduciary duties to the Company
and/or its stockholders by voting as a director or taking any other action
whatsoever in Stockholder’s capacity as a director or officer of the Company.

 

Section 2.5             No Transfer of Subject Shares; Publicity.  Stockholder agrees that:

 

(a)           Stockholder (i) shall not
Transfer or agree to Transfer any of the Subject Shares or, with respect to any
matter described in Section 2.2(a), grant any proxy or 

 

3

 

power-of-attorney with respect
to any of the Subject Shares, (ii) shall take all action reasonably
necessary to prevent creditors in respect of any pledge of the Subject Shares
from exercising their rights under such pledge, and (iii) shall not take
any action that would make in a material respect any of its representations or
warranties contained herein untrue or incorrect or would have the effect of
preventing or disabling the Stockholder from performing any of its material
obligations hereunder.  Notwithstanding
the foregoing, Stockholder may Transfer and agree to Transfer any of the
Subject Shares provided that each person to which any such Subject Shares are
Transferred shall have (x) executed a counterpart of this Agreement and a
Proxy in the form attached hereto as Exhibit A (with such modifications as
BioSante may reasonably request), and (y) agreed in writing to hold such
Subject Shares subject to all of the terms and conditions set forth in this
Agreement.

 

(b)           Unless required by applicable Law or
permitted by the Merger Agreement, Stockholder shall not, and shall not
authorize or direct any of its Affiliates or Representatives to, make any press
release or public announcement with respect to this Agreement or the Merger
Agreement or the transactions contemplated hereby or thereby, without the prior
written consent of BioSante in each instance.

 

ARTICLE III

REPRESENTATIONS, WARRANTIES AND ADDITIONAL COVENANTS

OF STOCKHOLDER

 

Stockholder represents, warrants and covenants to
BioSante that:

 

Section 3.1             Ownership.  Stockholder is the sole Beneficial Owner and
the record and legal owner of the Subject Shares identified on Schedule A and
such shares constitute all of the capital stock of the Company Beneficially
Owned by Stockholder.  Stockholder has
good and valid title to all of such shares, free and clear of all Liens,
claims, options, proxies, voting agreements and security interests and has the
sole right to such Subject Shares and there are no restrictions on rights of
disposition or other Liens pertaining to such Subject Shares.  None of the Subject Shares is subject to any
voting trust or other contract with respect to the voting thereof, and no
proxy, power of attorney or other authorization has been granted with respect
to any of such Subject Shares.

 

Section 3.2             Authority and Non-Contravention.

 

(a)           Stockholder is an individual, and not a corporation,
limited liability company, partnership, trust or other such entity.  Stockholder has all necessary legal capacity
to execute and deliver this Agreement and to perform its obligations
hereunder and to consummate the transactions contemplated hereby.

 

(b)           Assuming
due authorization, execution and delivery of this Agreement by BioSante, this
Agreement has been duly and validly executed and delivered by Stockholder and
constitutes the legal, valid and binding obligation of Stockholder, enforceable
against Stockholder in accordance with its terms except (i) to the extent
limited by applicable bankruptcy, insolvency or similar laws affecting
creditors’ rights and (ii) the remedy of specific 

 

4

 

performance and injunctive and other forms of equitable relief may be
subject to equitable defenses and to the discretion of the court before which
any proceeding therefor may be brought.

 

(c)           Stockholder
is not nor will it be required to make any filing with or give any notice to,
or to obtain any consent from, any person in connection with the execution,
delivery or performance of this Agreement or obtain any permit or approval from
any Governmental Authority for any of the transactions contemplated hereby,
except to the extent required by Section 13 or Section 16 of the
Exchange Act and the rules promulgated thereunder.

 

(d)           Neither
the execution and delivery of this Agreement by Stockholder nor the
consummation of the transactions contemplated hereby will directly or
indirectly (whether with notice or lapse of time or both) (i) conflict
with, result in any violation of or constitute a default by Stockholder under
any mortgage, bond, indenture, agreement, instrument or obligation to which
Stockholder is a party or by which it or any of the Subject Shares are bound,
or violate any permit of any Governmental Authority, or any Law or Order to
which Stockholder, or any of the Subject Shares, may be subject, or (ii) result
in the imposition or creation of any Lien upon or with respect to any of the
Subject Shares; except, in each case, for conflicts, violations, defaults or
Liens that would not individually or in the aggregate be reasonably expected to
prevent or materially impair or delay the performance by the Stockholder of its
obligations hereunder.

 

(e)           Stockholder has sole
voting power and sole power to issue instructions with respect to the matters
set forth in Article II hereof and sole power to agree to all of the
matters set forth in this Agreement, in each case with respect to all of the
Subject Shares, with no limitations, qualifications or restrictions on such
rights.

 

Section 3.3             Total Shares.  Except as set forth on Schedule A,
Stockholder is not the Beneficial Owner of, and does not have (whether
currently, upon lapse of time, following the satisfaction of any conditions,
upon the occurrence of any event or any combination of the foregoing) any right
to acquire, and has no other interest in or voting rights with respect to, any
Company Shares or any securities convertible into or exchangeable or
exercisable for Company Shares.

 

Section 3.4             Reliance.  Stockholder understands and acknowledges that
BioSante is entering into the Merger Agreement in reliance upon Stockholder’s
execution, delivery and performance of this Agreement.

 

ARTICLE IV

REPRESENTATIONS, WARRANTIES AND COVENANTS OF BIOSANTE

 

BioSante represents, warrants and covenants to
Stockholder that, assuming due authorization, execution and delivery of this
Agreement by Stockholder, this Agreement constitutes the legal, valid and
binding obligation of BioSante, enforceable against BioSante in accordance with
its terms, except (i) to the extent limited by applicable bankruptcy,
insolvency or similar laws affecting creditors’ rights and (ii) the remedy
of specific performance and injunctive and other forms of equitable relief may
be subject to equitable defenses and to the discretion of the court before
which any proceeding therefor may be brought. BioSante has the corporate power
and authority to execute and deliver this Agreement and to perform its 

 

5

 

obligations hereunder.  The execution and delivery by BioSante of
this Agreement and the consummation by BioSante of the transactions
contemplated hereby have been duly and validly authorized by BioSante and no
other corporate proceedings on the part of BioSante are necessary to authorize
this Agreement or to consummate the transactions contemplated hereby.  This Agreement has been duly and validly
executed and delivered by BioSante.

 

ARTICLE V

GENERAL PROVISIONS

 

Section 5.1             No Ownership Interest.  Nothing contained in this Agreement shall be
deemed to vest in BioSante or any of its Affiliates any direct or indirect
ownership or incidents of ownership of or with respect to the Subject
Shares.  All rights, ownership and
economic benefits of and relating to the Subject Shares shall remain and belong
to Stockholder, and neither BioSante nor any of its Affiliates shall have any authority
to manage, direct, superintend, restrict, regulate, govern or administer any of
the policies or operations of the Company or exercise any power or authority to
direct Stockholder in the voting of any of the Subject Shares, except as
otherwise expressly provided herein or in the Merger Agreement.

 

Section 5.2             Notices.  All notices, consents, waivers and other
communications under this Agreement shall be in writing (including facsimile or
similar writing) and shall be given:

 

(a)           If to BioSante, to:

 

BioSante
Pharmaceuticals, Inc.

Suite 280

111
Barclay Boulevard

Lincolnshire,
IL 60069

Attention:  Phillip B. Donenberg

Facsimile No:  (847) 478-9263

with
a copy (which shall not constitute notice) to:

 

Oppenheimer Wolff &
Donnelly LLP

Plaza VII, Suite 3300

45
South Seventh Street

Minneapolis,
MN 55402

Attention:  Amy E. Culbert, Esq.

Facsimile No:  (612) 607-7100

 

(b)           If
to a Stockholder, to Stockholder’s address set forth on Schedule A.

 

or such other address or facsimile number as a
party may hereafter specify for the purpose by notice to the other parties
hereto.  Each notice, consent, waiver or
other communication under this Agreement shall be effective only (a) if
given by facsimile, when the facsimile is transmitted to the facsimile number
specified in this Section and the appropriate facsimile confirmation is
received or (b) if given by overnight courier or personal delivery when
delivered at the address specified in this Section.

 

6

 

Section 5.3             Further Actions.  Upon the request of any party to this
Agreement, the other party will (a) furnish to the requesting party any
additional information, (b) execute and deliver, at their own expense, any
other documents and (c) take any other actions as the requesting party may
reasonably require to more effectively carry out the intent of this Agreement.

 

Section 5.4             Entire Agreement and Modification.  This Agreement, the Proxy and any other
documents delivered by the parties in connection herewith constitute the entire
agreement between the parties with respect to the subject matter hereof and
supersede all prior agreements and understandings, both written and oral,
between the parties with respect to its subject matter and constitute (along
with the documents delivered pursuant to this Agreement) a complete and
exclusive statement of the terms of the agreement between the parties with
respect to its subject matter. This Agreement shall not be amended,
supplemented or otherwise modified except by a written document executed by the
party against whose interest the modification will operate.  The parties shall not enter into any other
agreement inconsistent with the terms and conditions of this Agreement and the
Proxy, or that addresses any of the subject matters addressed in this Agreement
and the Proxy.

 

Section 5.5             Drafting and Representation.  The parties agree that the terms and language
of this Agreement were the result of negotiations between the parties and, as a
result, there shall be no presumption that any ambiguities in this Agreement
shall be resolved against any party.  Any
controversy over construction of this Agreement shall be decided without regard
to events of authorship or negotiation.

 

Section 5.6             Severability.  Any provision of this Agreement which is
prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without
affecting the validity or enforceability of the remaining provisions
hereof.  Any such prohibition or
unenforceability in any jurisdiction shall not invalidate or render
unenforceable such provision in any other jurisdiction.  If any provision of this Agreement is so
broad as to be unenforceable, the provision shall be interpreted to be only so
broad as is enforceable.

 

Section 5.7             No Third-Party Rights.  Stockholder may not assign any of its rights
or delegate any of its obligations under this Agreement without the prior
written consent of BioSante.  BioSante
may not assign any of their rights or delegate any of their obligations under
this Agreement with respect to Stockholder without the prior written consent of
Stockholder.  This Agreement will apply
to, be binding in all respects upon, and inure to the benefit of each of the
respective successors, personal or legal representatives, heirs, distributes,
devisees, legatees, executors, administrators and permitted assigns of
Stockholder and the successors and permitted assigns of BioSante.  Nothing expressed or referred to in this
Agreement will be construed to give any person, other than the parties to this
Agreement, any legal or equitable right, remedy or claim under or with respect
to this Agreement or any provision of this Agreement except such rights as may
inure to a successor or permitted assignee under this Section.

 

Section 5.8             Enforcement of Agreement.  Stockholder acknowledges and agrees that
BioSante could be damaged irreparably if any of the provisions of this
Agreement are not performed in accordance with their specific terms and that
any breach of this Agreement by 

 

7

 

Stockholder could not be adequately compensated by monetary
damages.  Accordingly, Stockholder agrees
that, (a) it will waive, in any action for specific performance, the
defense of adequacy of a remedy at Law, and (b) in addition to any other
right or remedy to which BioSante may be entitled, at Law or in equity,
BioSante will be entitled to enforce any provision of this Agreement by a
decree of specific performance and to temporary, preliminary and permanent
injunctive relief to prevent breaches or threatened breaches of any of the
provisions of this Agreement, without posting any bond or other undertaking.

 

Section 5.9             Waiver.  The rights and remedies of the parties to
this agreement are cumulative and not alternative.  Neither any failure nor any delay by a party
in exercising any right, power or privilege under this Agreement, the Proxy or
any of the documents referred to in this Agreement will operate as a waiver of
such right, power or privilege, and no single or partial exercise of any such
right, power or privilege will preclude any other or further exercise of such
right, power or privilege or the exercise of any other right, power or
privilege.  To the maximum extent permitted
by Law, (a) no claim or right arising out of this Agreement, the Proxy or
any of the documents referred to in this Agreement can be discharged by one
party, in whole or in part, by a waiver or renunciation of the claim or right
unless in a written document signed by the other party, (b) no waiver that
may be given by a party will be applicable except in the specific instance for
which it is given, and (c) no notice to or demand on one party will be
deemed to be a waiver of any obligation of that party or of the right of the
party giving such notice or demand to take further action without notice or
demand as provided in this Agreement, the Proxy or the documents referred to in
this Agreement.

 

Section 5.10           Governing Law.  This Agreement and all acts and transactions
pursuant hereto and the rights and obligations of the parties hereto will be
governed by, construed under and interpreted in accordance with the Laws of the
State of Delaware, without giving effect to principles of conflicts or choice
of law.

 

Section 5.11           Consent to Jurisdiction.  Any suit, action or proceeding seeking to
enforce any provision of, or based on any matter arising out of or in
connection with, this Agreement, the Proxy or the transactions contemplated
hereby or thereby shall be brought exclusively in the United States District
Court for the District of Delaware or, if such court does not have jurisdiction
over the subject matter of such proceeding or if such jurisdiction is not
available, in the Court of Chancery of the State of Delaware, County of New
Castle, and each of the parties hereby consents to the exclusive jurisdiction
of those courts (and of the appropriate appellate courts therefrom) in any
suit, action or proceeding and irrevocably waives, to the fullest extent
permitted by Law, any objection which it may now or hereafter have to the
laying of the venue of any suit, action or proceeding in any of those courts or
that any suit, action or proceeding which is brought in any of those courts has
been brought in an inconvenient forum. Process in any suit, action or
proceeding may be served on any party anywhere in the world, whether within or
without the jurisdiction of any of the named courts.  Without limiting the foregoing, each party
agrees that service of process on it by notice as provided in Section 5.2 shall
be deemed effective service of process. 
EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY LAW, ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, PROCEEDING
OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF
OR 

 

8

 

RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED
HEREBY.

 

Section 5.12           Counterparts.  This Agreement may be executed in one or more
counterparts, each of which shall be deemed to be an original, but all of
which, taken together, shall constitute one and the same instrument.  This Agreement may be executed by facsimile
signature (including signatures in Adobe PDF or similar format).

 

Section 5.13           Termination.  This Agreement shall terminate upon the
earliest of (a) the Effective Time (as defined in the Merger Agreement), (b) the
termination of the Merger Agreement in accordance with Article IX thereof,
or (c) written notice by BioSante to Stockholder of the termination of
this Agreement (the date of the earliest of the events described in
clauses (a), (b) and (c), the “Expiration Date”).

 

Section 5.14           Expenses.  Except as otherwise provided in this
Agreement, all costs and expenses incurred in connection with this Agreement
and the transactions contemplated hereby shall be paid by the party incurring
such expenses.

 

Section 5.15           Headings; Construction.  The headings contained in this Agreement are
for reference purposes only and shall not affect in any way the meaning or interpretation
of this Agreement.  In this Agreement (a) words
denoting the singular include the plural and vice versa, (b) “it” or “its”
or words denoting any gender include all genders and (c) the word “including”
shall mean “including without limitation,” whether or not expressed.

 

[SIGNATURE PAGE FOLLOWS]

 

9

 

IN WITNESS WHEREOF, the parties hereto have caused this
Voting Agreement to be duly executed as of the day and year first above
written.

 

	
  BIOSANTE:

  	
  BIOSANTE
  PHARMACEUTICALS, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  Stephen M. Simes

  
	
   

  	
   

  	
  Name:
  Stephen M. Simes

  
	
   

  	
   

  	
  Title:
  Vice Chairman, President and Chief Executive Officer

  
	
   

  	
   

  	
   

  
	
  STOCKHOLDER:

  	
  STEPHEN
  A. SHERWIN, M.D.

  
	
   

  	
   

  
	
   

  	
  /s/
  Stephen A. Sherwin, M.D.

  
	
   

  	
  Name:
  Stephen A. Sherwin, M.D.

  
	
   

  	
   

  
	
   

  	
  Additional
  Signature (if held jointly):

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  (If
  held jointly)

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  (Printed
  Full Name)

  

 

[Signature
page to Voting Agreement]

 

 

SCHEDULE
A

 

	
  NAME AND

  ADDRESS OF STOCKHOLDER

  	
   

  	
  COMPANY SHARES

  BENEFICIALLY OWNED

  	
   

  
	
  Stephen A. Sherwin, M.D.  

  3508 Clay
  Street  

  San
  Francisco, CA  94118

  	
   

  	
  474,621

  	
  (1)

  

 

(1)           Comprised of shares held by The
Sherwin Family Trust.  Excludes
1,017,500 shares subject to exercise of options. Also excludes
30,000 shares held by The Sherwin Irrevocable Children’s Trust (for which Dr. Sherwin
does not have beneficial ownership or voting authority).

 

 

EXHIBIT
A

 

IRREVOCABLE PROXY

 

From and after the date hereof and until the Expiration
Date (as defined below), the undersigned stockholder (“Stockholder”) of
Cell Genesys, Inc., a Delaware corporation (the “Company”), hereby
irrevocably (to the full extent permitted by Section 212 of the Delaware
General Corporation Law) grants to, and appoints, BioSante Pharmaceuticals, Inc.,
a Delaware corporation (“BioSante”), and any designee of BioSante, and
each of them individually, as the sole and exclusive attorney and proxy of the
undersigned, with full power of substitution and resubstitution, to vote the
Subject Shares (as defined in the Voting Agreement) of the Stockholder, or
grant a consent or approval in respect of the Subject Shares of the
Stockholder, in a manner consistent with Section 2.2 of the Voting
Agreement (as defined below).  Upon the
undersigned’s execution of this Proxy, any and all prior proxies given by the
undersigned with respect to any Subject Shares relating to the voting rights
expressly provided herein are hereby revoked and the undersigned agrees not to
grant any subsequent proxies with respect to the Subject Shares relating to
such voting rights at any time prior to the Expiration Date.

 

This Proxy is irrevocable, is coupled with an interest
and is granted pursuant to that certain Voting Agreement (as amended from time
to time, the “Voting Agreement”) of even date herewith, by and among
BioSante and Stockholder, and is granted in consideration of BioSante entering
into the Merger Agreement (as defined in the Voting Agreement). As used herein,
the term “Expiration Date,” and all capitalized terms used herein and
not otherwise defined, shall have the meanings set forth in the Voting
Agreement.  The
Stockholder agrees that this proxy shall be irrevocable until the Expiration
Date and is coupled with an interest sufficient at law to support an
irrevocable proxy and given to BioSante as an inducement to enter into the
Merger Agreement and, to the extent permitted under applicable law, shall be
valid and binding on any person to whom Stockholder may transfer any of his,
her or its Subject Shares in breach of the Voting Agreement.  The Stockholder hereby ratifies
and confirms all that such irrevocable proxy may lawfully do or cause to be
done by virtue hereof.

 

The attorneys and proxies named above, and each of them,
are hereby authorized and empowered by the undersigned, at any time prior to
the Expiration Date, to act as the undersigned’s attorney and proxy to vote the
Subject Shares, and to exercise all voting and other rights of the undersigned
with respect to the Subject Shares (including, without limitation, the power to
execute and deliver written consents pursuant to Section 228 of the
Delaware General Corporation Law), at every annual, special or adjourned
meeting of the stockholders of the Company and in every written consent in lieu
of such meeting in a manner consistent with Section 2.2 of the Voting
Agreement.

 

This Proxy shall be binding upon the heirs, estate,
executors, personal representatives, successors and assigns of Stockholder
(including any transferee of any of the Subject Shares), and all authority
herein conferred or agreed to be conferred shall survive the death or
incapacity of the Stockholder.

 

 

If any provision of this Proxy or any part of any such
provision is held under any circumstances to be invalid or unenforceable in any
jurisdiction, then (a) such provision or part thereof shall, with respect
to such circumstances and in such jurisdiction, be deemed amended to conform to
applicable laws so as to be valid and enforceable to the fullest possible
extent, (b) the invalidity or unenforceability of such provision or part
thereof under such circumstances and in such jurisdiction shall not affect the
validity or enforceability of such provision or part thereof under any other
circumstances or in any other jurisdiction, and (c) the invalidity or
unenforceability of such provision or part thereof shall not affect the
validity or enforceability of the remainder of such provision or the validity
or enforceability of any other provision of this Proxy. Each provision of this
Proxy is separable from every other provision of this Proxy, and each part of
each provision of this Proxy is separable from every other part of such
provision.

 

Dated:  June 29,
2009

 

	
   

  	
  /s/ Stephen A.
  Sherwin, M.D.

  
	
   

  	
  (Signature of
  Stockholder)

  
	
   

  	
   

  
	
   

  	
  Stephen A.
  Sherwin, M.D.

  
	
   

  	
  (Print Name of
  Stockholder)

  
	
   

  	
   

  
	
   

  	
  Number of Subject
  Shares owned of record or Beneficially Owned as of the date of this Proxy:

  
	
   

  	
   

  
	
   

  	
  474,621

  
	
   

  	
   

  

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}]]